The HSD3B1 (1245C) allele is linked to androgen deprivation therapy (ADT) resistance among patients with prostate cancer, according to a study published in The Lancet Oncology.1

Researchers conducted a multicohort study that retrospectively examined 443 men who were treated with ADT for biochemical failure or non-metastatic clinical failure and who had the HSD3B1 allele.

Multivariable analyses were conducted to determine the independent predictive value of the genotype on patient outcomes, specifically progression-free survival.

The researchers found that, in the primary study cohort that included 118 patients who underwent prostatectomy, median progression-free survival decreased with respect to the number of variant alleles inherited, with 6.6 years in men with homozygous wild-type genotype, 4.1 years with heterozygous variant genotype, and 2.5 years with homozygous variant genotype.

RELATED: Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer

Regarding the homozygous wild-type genotype, inheriting 1 or 2 copies of the variant allele was predictive of lower progression-free survival.

Findings were independently confirmed in validation cohorts, with similar results for distant metastasis-free survival and overall survival.

Reference

  1. Hearn JW, AbuAli G, Reichard CA, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016. doi: 10.1016/S1470-2045(16)30227-3 [Epub ahead of print]